Zoetis Inc., ZTS is in the exchange NYSE and its industry is Drugs – Generic in the sector of Healthcare. Based in USA, Zoetis Inc., ZTS has a market cap of 25677.72. Since its IPO date on the 2/1/2013, Zoetis Inc., ZTS performance year to date is 8.93%. Today Zoetis Inc., ZTS has gained 1.29%, with a current price of 51.87.
Ownership of the company is 0.01% for insider ownership while institutional ownership is 95.50%. The management of the company have seen the company have a payout ratio of 35.10%. Return of assets are at 8.60%, with return on investment at 5.70%.
In terms of debt levels and profit levels, Zoetis Inc., ZTS is seeing a long-term debt/equity of 3.29. While Total debt/equity is 3.29. With a profit margin of 13.20%, this is combined with a gross margin of 64.90%, and operating margin of 20.70%. Zoetis Inc. ability to meet debt levels, with a current ratio of 3.2, while the quick ratio is 1.7.
For the last year Zoetis Inc., ZTS has seen a EPS growth of -31.60%. A performance for the year of 30.88%. The 52-week high is -1.46%, and the 52-week low is 36.14%. The average volume for Zoetis Inc., ZTS is 3201900.
With a target price of 54.5, can Zoetis Inc., ZTS reach this target? Looking at the value indicators of Zoetis Inc., ZTS. Zoetis Inc. has a P/E of 40.52 and a forward P/E of 22.4. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.22. Zoetis Inc. also has a P/S and a P/B of 5.29 and 19 respectively. For P/cash, Zoetis Inc. has a value of 39.02, while it is 52.4 for P/free cash flow.
At the current price of 51.87, Zoetis Inc. has a dividend yield of 0.73%. We see a return on equity of 53.00%.
Looking more long-term Zoetis Inc., is projected to get an EPS growth for the next five years of 12.58%. In the short-term an EPS growth of 21.96% in the next year is forecasted. This is after a EPS growth of -31.60% for this year and for the last five years a 29.30% growth has been seen.